【中国生物制药早盘上涨 3.95%,现报 3.16 港元,成交额 2.18 亿港元】2 月 7 日,中国生物制药集团开发的“洛索洛芬钠凝胶贴膏”获中国国家药品监督管理局上市批准,用于骨关节炎等疾病及症状的消炎、镇痛。其是国内唯一一款通过一致性评价且经临床试验验证上市的洛索洛芬钠凝胶贴膏。洛索洛芬钠通过抑制环氧化酶等起作用。 同日,中国生物制药集团开发的“妥洛特罗贴剂”获中国国家药品监督管理局上市...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.